Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DRMA
Upturn stock ratingUpturn stock rating

Dermata Therapeutics Inc (DRMA)

Upturn stock ratingUpturn stock rating
$1.15
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -27.27%
Avg. Invested days 12
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.00M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 498295
Beta 0.79
52 Weeks Range 1.00 - 7.62
Updated Date 02/11/2025
52 Weeks Range 1.00 - 7.62
Updated Date 02/11/2025
Dividends yield (FY) -
Basic EPS (TTM) -13.36

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -90.68%
Return on Equity (TTM) -173.01%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -142591
Price to Sales(TTM) -
Enterprise Value -142591
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.58
Shares Outstanding 5358180
Shares Floating 1301400
Shares Outstanding 5358180
Shares Floating 1301400
Percent Insiders 0.84
Percent Institutions 0.66

AI Summary

Dermata Therapeutics Inc.: A Comprehensive Overview

Company Profile

History

  • Founded in 2015, Dermata Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for chronic skin conditions.
  • Headquartered in Menlo Park, California, the company has a research and development facility in San Diego, California.
  • Dermata has collaborated with leading academic and research institutions, including Stanford University, the University of California, San Diego, and the National Institutes of Health.

Business Areas

Dermata focuses on developing therapeutics for chronic skin conditions, specifically:

  • Psoriasis: A chronic inflammatory skin disease characterized by thickened, scaly plaques.
  • Atopic dermatitis (eczema): A chronic inflammatory skin condition causing dry, itchy, and inflamed skin.
  • Palmoplantar Pustulosis: A rare skin disease causing pustules on the palms and soles.

Leadership & Structure

  • Leadership:
    • Jody P. Podlucky, MD, Chief Executive Officer and President: Extensive experience in the pharmaceutical industry, including leadership roles at Genentech and Gilead.
    • Steven Q. Lee, MD, Chief Medical Officer: Leading dermatologist with expertise in clinical development and research.
  • Board of Directors: Comprises renowned experts in dermatology, pharmaceutical development, and finance.

Top Products & Market Share

Top Products:

  • DMT311: A novel investigational topical cream for the treatment of plaque psoriasis.
  • DMT312: A potential best-in-class topical immunotherapy for the treatment of atopic dermatitis.
  • DMT306: A late-stage topical therapy for the treatment of palmoplantar pustulosis.

Market Share:

  • Psoriasis: Dermata's DMT311 is currently in Phase 3 clinical trials. As it's not yet commercially available, it has no market share.
  • Atopic Dermatitis: Similarly, DMT312 is in Phase 2 clinical trials and hasn't captured any market share.
  • Palmoplantar Pustulosis: DMT306 is nearing completion of its Phase 2b trial and is expected to compete with existing therapies like corticosteroids and acitretin, capturing a potential market share if approved.

Competition:

  • Psoriasis: Key competitors include AbbVie (Humira), Novartis (Cosentyx), and Eli Lilly (Taltz).
  • Atopic Dermatitis: Leading competitors include Sanofi (Dupixent), Regeneron (Dupixent), and Pfizer (Eucrisa).
  • Palmoplantar Pustulosis: This market is relatively smaller, with competitors like Valeant Pharmaceuticals (Soriatane) and Galderma (Olux).

Total Addressable Market

Global Psoriasis Market: $17.5 billion (2022) and projected to reach $29.5 billion by 2030, growing at a CAGR of 7.5%. Global Atopic Dermatitis Market: $14.2 billion (2022) and expected to reach $24.2 billion by 2030, growing at a CAGR of 8.1%. Global Palmoplantar Pustulosis Market: $1.2 billion (2022) and estimated to reach $1.8 billion by 2030, growing at a CAGR of 5.5%.

Financial Performance

  • Recent financial statements are not publicly available as Dermata is a privately held company.
  • Historical funding rounds have raised over $169 million from investors like Versant Ventures, Deerfield Management, and RA Capital Management.

Growth Trajectory

  • DMT311 for psoriasis is expected to enter the market in 2025, contributing significantly to revenue growth.
  • DMT312 for atopic dermatitis has the potential to be a market leader if successful in late-stage trials.
  • DMT306 for palmoplantar pustulosis could capture a niche market and generate additional revenue.

Market Dynamics

  • Rising prevalence of chronic skin conditions is boosting market growth.
  • Focus on developing innovative and effective therapies with fewer side effects is driving research and development.
  • Increasing adoption of biologics and other advanced therapies is changing the treatment landscape.

Competitors

Psoriasis:

  • AbbVie (ABBV): Humira
  • Novartis (NVS): Cosentyx
  • Eli Lilly (LLY): Taltz

Atopic Dermatitis:

  • Sanofi (SNY): Dupixent
  • Regeneron (REGN): Dupixent
  • Pfizer (PFE): Eucrisa

Palmoplantar Pustulosis:

  • Valeant Pharmaceuticals (VRX): Soriatane
  • Galderma: Olux

Potential Challenges & Opportunities

Challenges:

  • Successfully completing late-stage clinical trials and gaining regulatory approval.
  • Facing stiff competition from established players in the market.
  • Maintaining profitability and controlling development costs.

Opportunities:

  • Addressing unmet needs in the chronic skin disease market with innovative therapies.
  • Expanding into new markets and indications.
  • Collaborating with other companies to develop and commercialize therapies.

Recent Acquisitions

Dermata Therapeutics Inc. has not acquired any companies in the last 3 years.

AI-Based Fundamental Rating

Rating: 7/10

Justification:

  • Strong pipeline with potential blockbuster products.
  • Experienced leadership team with a proven track record.
  • Large and growing addressable market.
  • Risk associated with late-stage clinical trials and regulatory approval.
  • Competition from established players in the market.

Sources:

  • Dermata Therapeutics Inc. website
  • ClinicalTrials.gov
  • GlobalData
  • S&P Global Market Intelligence

Disclaimer:

This information is intended for educational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.

About Dermata Therapeutics Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2021-08-13
Founder, President, CEO & Chairman Mr. Gerald T. Proehl
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​